Protalix to trial nerve gas treatment
The drug will probably only have to undergo Phase I trials.
The company also reported that the results of a trial of its treatment for Gaucher's disease showed that it was superior to the corresponding drug produced by Genzyme in penetration to the target cells.
Protalix also has in its pipeline of products a drug for the treatment of Fabry disease, and a treatment for arthritis.
Investment house HalmanAldubi began coverage of Protalix today with an unusually positive report. The investment house sees potential upside of over 100% in the company. Protalix's market cap is currently $540 million, HalmanAldubi's target price of $15 reflects a value of $1.3 billion. The report said that the share price did not reflect the added value of Protalix's technology platform, and called Protalix "the next Teva."
Published by Globes [online], Israel business news - www.globes-online.com - on January 24, 2010
© Copyright of Globes Publisher Itonut (1983) Ltd. 2010
- Tel Aviv market report
- Tel Aviv Stock Exchange
- Israeli stocks in NY
- Arbitrage gaps for dual-listed stocks
- Israeli stocks in Europe
- Israeli stocks on other markets
- Tel Aviv 25 options
- Mutual funds
- Current representative shekel rates
- Historical representative shekel rates
- Bank shekel rates
- Shekel/dollar options